Differential (Click to cross reference) aducanumab advances in neurology Alzheimer's disease Alzheimer's disease, pathogenesis Alzheimer's disease, treatment of amyloid amyloid angiopathy, cerebral amyloid angiopathy, cerebral, inflammatory type amyloid beta protein amyloid beta protein antibodies amyloid deposition amyloid plaques amyloid-related imaging abnormalities anti-amyloid therapy apolipoprotein E biologic markers CAT scan, emission CAT scan, emission, abnormal cerebral cortical atrophy cerebral edema, vasogenic complications contraindications controversies in neurology cost dementia disease modifying agents enzyme inhibition memory, impairment of microhemorrhage, intracerebral mild cognitive impairment monoclonal antibodies MRI MRI, abnormal negative Pittsburgh Compound B prevention of neurologic disorders review article safety shared decision making temporal lobe treatment of neurologic disorder white matter disease

Showing articles 0 to 6 of 6 Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021 Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road? NEJM 370:377-378, Karran, E. & Hardy, J., 2014 Anti-Ab Autoantibodies in the CSF of a Patient With CAA-Related Inflammation: A Case Report Neurol 76:842-844, DiFrancesco,J.C.,et al, 2011 In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009 Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon Practical Neurology 7:16-23, Christensen,D.B., 2008 Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008 Showing articles 0 to 6 of 6